Zyn
Coverage of Zyn in the Nexus archive.
- Tobacco companies are cashing in on Zyn’s unstoppable popularity
Tobacco companies are capitalizing on the rising popularity of Zyn, a nicotine pouch product. Sales of nicotine pouches are projected to surge from $6.9 billion in 2025 to over $40 billion worldwide by 2033, according to an analysis.
- FDA authorizes 20 ZYN nicotine pouches to be marketed with modified risk claim
The FDA authorized 20 ZYN nicotine pouches to carry a modified risk claim. This allows the product to be marketed with a label indicating reduced health risks compared to traditional tobacco products.
- FDA says Zyn can market its pouches as safer than cigarettes
The FDA has approved Zyn to market its nicotine pouches as safer than cigarettes. The article also mentions STAT’s free health newsletter and a temporary substitution in its editorial team.
- Are ZYN nicotine pouches safer than smoking? FDA weighs in
The FDA conducted a survey indicating that ZYN nicotine pouches are the most popular among middle and high school students who use such products. The FDA is evaluating whether ZYN nicotine pouches are safer than smoking.
- France bans Zyns and other nicotine pouches — with violators facing 5 years in prison and a shocking fine
France has banned the use, acquisition, possession, and sale of oral nicotine products like Zyn pouches and gum lozenges, with violators facing up to 5 years in prison and heavy fines.
- The Tech Bros Are All In on Zyn
Tech workers are embracing Zyn nicotine pouches, which they claim enhance productivity and focus. The product is marketed as a brain-boosting and productivity-boosting stimulant.